$950 Million is the total value of VR Adviser, LLC's 37 reported holdings in Q3 2023. The portfolio turnover from Q2 2023 to Q3 2023 was 43.3% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| New | APOGEE THERAPEUTICS INC | $180,907,737 | – | 8,493,321 | +100.0% | 19.04% | – | |
| New | RAYZEBIO INC | $89,174,003 | – | 4,016,847 | +100.0% | 9.39% | – | |
| VRDN | VIRIDIAN THERAPEUTICS INC | $47,287,421 | -35.5% | 3,082,622 | 0.0% | 4.98% | -57.6% | |
| COGT | Buy | COGENT BIOSCIENCES INC | $45,670,628 | -17.7% | 4,684,167 | +0.0% | 4.81% | -45.8% |
| TSHA | New | TAYSHA GENE THERAPIES INC | $45,644,443 | – | 14,444,444 | +100.0% | 4.80% | – |
| MRUS | MERUS N V | $40,704,126 | -10.4% | 1,726,214 | 0.0% | 4.28% | -41.0% | |
| Buy | ENLIVEN THERAPEUTICS INC | $40,363,961 | -11.3% | 2,954,902 | +32.5% | 4.25% | -41.6% | |
| FDMT | 4D MOLECULAR THERAPEUTICS IN | $38,190,000 | -29.6% | 3,000,000 | 0.0% | 4.02% | -53.6% | |
| PHVS | Buy | PHARVARIS N V | $32,630,516 | +62.5% | 1,563,513 | +17.9% | 3.44% | +7.0% |
| CABA | Buy | CABALETTA BIO INC | $30,032,911 | +17.9% | 1,973,253 | +0.0% | 3.16% | -22.4% |
| KALV | KALVISTA PHARMACEUTICALS INC | $28,087,503 | +7.0% | 2,916,667 | 0.0% | 2.96% | -29.6% | |
| GHRS | Sell | GH RESEARCH PLCordinary shares | $27,578,456 | -33.9% | 2,744,125 | -22.0% | 2.90% | -56.5% |
| New | HILLEVAX INC | $27,401,860 | – | 2,037,313 | +100.0% | 2.88% | – | |
| SVRA | Buy | SAVARA INC | $27,158,790 | +33.8% | 7,184,865 | +13.1% | 2.86% | -11.9% |
| RYTM | RHYTHM PHARMACEUTICALS INC | $24,988,250 | +39.0% | 1,090,000 | 0.0% | 2.63% | -8.5% | |
| AMAM | Sell | AMBRX BIOPHARMA INCsponsored ads | $23,805,000 | -41.8% | 2,070,000 | -16.7% | 2.51% | -61.7% |
| TVTX | New | TRAVERE THERAPEUTICS INC | $23,455,672 | – | 2,623,677 | +100.0% | 2.47% | – |
| DYN | DYNE THERAPEUTICS INC | $19,478,260 | -20.4% | 2,173,913 | 0.0% | 2.05% | -47.6% | |
| CELC | CELCUITY INC | $19,243,228 | -16.8% | 2,105,386 | 0.0% | 2.03% | -45.2% | |
| TERN | Buy | TERNS PHARMACEUTICALS INC | $15,554,133 | -40.2% | 3,092,273 | +4.0% | 1.64% | -60.6% |
| MRSN | New | MERSANA THERAPEUTICS INC | $14,386,560 | – | 11,328,000 | +100.0% | 1.51% | – |
| APLT | APPLIED THERAPEUTICS INC | $14,088,505 | +94.5% | 5,658,034 | 0.0% | 1.48% | +28.1% | |
| ORIC | ORIC PHARMACEUTICALS INC | $12,964,279 | -22.0% | 2,142,856 | 0.0% | 1.36% | -48.7% | |
| New | DIANTHUS THERAPEUTICS INC | $12,681,741 | – | 927,706 | +100.0% | 1.34% | – | |
| ADVM | Buy | ADVERUM BIOTECHNOLOGIES INC | $9,859,950 | +59.6% | 6,573,300 | +69.1% | 1.04% | +5.1% |
| PRAX | PRAXIS PRECISION MEDICINES I | $9,070,541 | +48.7% | 5,304,410 | 0.0% | 0.96% | -2.1% | |
| New | ACELYRIN INC | $8,790,256 | – | 864,332 | +100.0% | 0.92% | – | |
| TRVI | TREVI THERAPEUTICS INC | $7,460,825 | -8.8% | 3,422,397 | 0.0% | 0.78% | -40.0% | |
| ACRS | ACLARIS THERAPEUTICS INC | $7,129,165 | -33.9% | 1,040,754 | 0.0% | 0.75% | -56.5% | |
| MIST | MILESTONE PHARMACEUTICALS IN | $6,847,317 | +8.8% | 2,208,812 | 0.0% | 0.72% | -28.4% | |
| PLRX | PLIANT THERAPEUTICS INC | $5,010,376 | -4.3% | 288,949 | 0.0% | 0.53% | -37.0% | |
| New | SAGIMET BIOSCIENCES INC | $4,532,000 | – | 515,000 | +100.0% | 0.48% | – | |
| LYRA | LYRA THERAPEUTICS INC | $3,613,505 | -4.9% | 924,170 | 0.0% | 0.38% | -37.4% | |
| AGLE | Sell | AEGLEA BIOTHERAPEUTICS INC | $3,614,167 | +26.5% | 295,034 | -95.3% | 0.38% | -16.8% |
| OLMA | New | OLEMA PHARMACEUTICALS INC | $951,469 | – | 77,042 | +100.0% | 0.10% | – |
| RALLYBIO CORP | $904,953 | -40.5% | 268,532 | 0.0% | 0.10% | -60.9% | ||
| AFMD | AFFIMED N V | $682,714 | -20.1% | 1,428,571 | 0.0% | 0.07% | -47.4% | |
| Exit | AVALO THERAPEUTICS INC | $0 | – | -1,250,000 | -100.0% | -0.07% | – | |
| BDTX | Exit | BLACK DIAMOND THERAPEUTICS I | $0 | – | -353,629 | -100.0% | -0.29% | – |
| Exit | THESEUS PHARMACEUTICALS INC | $0 | – | -770,000 | -100.0% | -1.15% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-11-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| ACLARIS THERAPEUTICS INC | 12 | Q3 2023 | 12.7% |
| VIRIDIAN THERAPEUTICS INC | 12 | Q3 2023 | 13.4% |
| COGENT BIOSCIENCES INC | 12 | Q3 2023 | 10.3% |
| RELMADA THERAPEUTICS INC | 11 | Q3 2022 | 9.9% |
| GH RESEARCH PLC | 10 | Q3 2023 | 6.7% |
| ALTIMMUNE INC | 9 | Q3 2022 | 11.6% |
| MARINUS PHARMACEUTICALS INC | 9 | Q4 2022 | 5.7% |
| CELLDEX THERAPEUTICS INC | 9 | Q3 2022 | 7.6% |
| AFFIMED N V | 8 | Q3 2023 | 1.1% |
| INSTIL BIO INC | 7 | Q3 2022 | 18.7% |
View VR Adviser, LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-11 |
| 13F-HR/A | 2023-05-15 |
| 13F-HR/A | 2023-05-15 |
| 13F-HR/A | 2023-05-15 |
| 13F-HR | 2023-05-15 |
| 13F-HR | 2023-02-14 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-15 |
View VR Adviser, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.